We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Retrospective Molecular Epidemiology Study in Singapore Patients With Advanced Non Small Cell Lung Cancer (NSCLC) of Adenocarcinoma Histology to Assess Epidermal Growth Factor Receptor (EGFR) Mutation Status

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified December 2013 by National University Hospital, Singapore.
Recruitment status was:  Recruiting
Sponsor:
ClinicalTrials.gov Identifier:
NCT01100827
First Posted: April 9, 2010
Last Update Posted: December 11, 2013
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
National University Hospital, Singapore
  Purpose

To determine EGFR mutation status in patients with advanced stage adenocarcinoma NSCLC.

To determine the association between EGFR mutation status and demographic data in advanced stage adenocarcinoma NSCLC patients.


Condition Intervention
NSCLC Other: EGFR mutation status in patients

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Retrospective

Resource links provided by NLM:


Further study details as provided by National University Hospital, Singapore:

Study Start Date: February 2013
Estimated Study Completion Date: February 2015
Estimated Primary Completion Date: February 2015 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
EGFR mutation status in patients Other: EGFR mutation status in patients

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   1 Year and older   (Child, Adult, Senior)
Sexes Eligible for Study:   All
Sampling Method:   Probability Sample
Study Population
In order to determine the EGFR mutation status, data analysis will be performed on demographic data and medical records (i.e. case notes and pathology reports) from patient with advanced stage adenocarcinoma NSCLC
Criteria

Inclusion Criteria:

Exclusion Criteria:

  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01100827


Contacts
Contact: Ross Andrew Soo, MBBS 65 6772 4624 ross_soo@nuhs.edu.sg

Locations
Singapore
National University Hospital Singapore Recruiting
Singapore, Singapore
Contact: Ross Andrew Soo, MBBS    65 6772 4624    ross_soo@nuhs.edu.sg   
Principal Investigator: Ross Soo, MBBS         
Sponsors and Collaborators
National University Hospital, Singapore
  More Information

Publications:
ClinicalTrials.gov Identifier: NCT01100827     History of Changes
Other Study ID Numbers: NS01/03/10
First Submitted: April 7, 2010
First Posted: April 9, 2010
Last Update Posted: December 11, 2013
Last Verified: December 2013

Keywords provided by National University Hospital, Singapore:
EGFR mutation status in patients with advanced stage adenocarcinoma NSCLC
The association between EGFR mutation status and demographic data in advanced stage adenocarcinoma NSCLC patients.

Additional relevant MeSH terms:
Adenocarcinoma
Carcinoma
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms